CD23 antigen expression on B lymphocytes and soluble CD23 levels in peripheral blood of high-risk type 1 diabetes subjects

Scandinavian Journal of Immunology

Volumn 49, Issue 1, 1999, Pages 78-81

  Krȩtowski, Adam ^a   Szelachowska, M ^b   Pietruczuk, M ^b   Kinalska, I ^b  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD23 ANTIGEN;

ADULT; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOPATHOGENESIS; INSULIN DEPENDENT DIABETES MELLITUS; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PROCESSING;

ADOLESCENT; ADULT; B-LYMPHOCYTES; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CHILD; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; PREDIABETIC STATE; RECEPTORS, IGE; RISK FACTORS; SOLUBILITY;

EID: 0032894194     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1999.00448.x     Document Type: Article

References (18)

1. 1 Noorehashm H, Kwok W, Rabinovitch A, Harrison LC. Immunology of IDDM. Diabetologia 1997;40:B50-7.
2. 2 Honeyman M, Wasserfall C, Nerup J, Rossini A. Prediction and prevention of IDDM. Diabetologia 1997;40:B58-61.
3. 3 Sayinalp S, Akalin S, Sayinalp N et al. Serum immunoglobulin E and soluble CD23 in patients with Graves' disease. Hormone Metab Res 1996;28:133-7.
4. 4 Shields J, Pachon S, Aubry JP et al. The role of CD23 and its receptor in T cell/B cell interaction: implications for regulation of IgE synthesis. Res Immunol 1992;143:425-7.
5. 5 Bansal A, Roberts T, Hay EM, Kay R, Dumphrey RSH, Wilson PB. Soluble CD23 levels are elevated in the serum of patients with primary Sjogren's syndrome and systemic lupus erythematosus. Clin Exp Immunol 1992;89:452-5.
6. + relatives: the ICARUS data set. Diabetes 1996;45:1720-8.
7. 7 Bingley PJ, Bonifacio E, Williams AJ, Genovese S, Botazzo GF, Gale EA. Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes 1997;46:1701-10.
8. 8 Hussain MJ, Maher J, Warnock T, Vats A, Peakman M, Vergani D. Cytokine overproduction in healthy first degree relatives of patients with IDDM. Diabetologia 1998;41:343-9.
9. 9 Itoh M, Shimazaki K, Hayakawa N et al. Expression of surface CD8 and CD23 production of soluble forms in IDDM patients with antibodies to GAD. Diabetologia 1997;40(Suppl. 1):A91.
10. 10 Szelachowska M, Kretowski A, Kinalska I. Decreased in vitro IL-4 and IL-10 production by peripheral blood in first degree relatives at high risk of diabetes type 1. Hormone Metab Res 1998;30:526-30.
11. 11 Berman MA, Sandborg CI, Wang Z et al. Decreased IL-4 production in new onset type I insulin-dependent diabetes mellitus. J Immunol 1996;157:4690-6.
12. 12 Avanzini MA, Vitali L, Strigazzi C, d'Annunzio G, Scaramuzza A, Lorini R. Increased serum sCD23 and CD23 cell surface expression in prediabetic subjects. Autoimmunity 1995;21:63.
13. 13 Verge CF, Gianani R, Kawasaki E et al. Prediction of type 1 diabetes in first degree relatives using a combination of insulin, GAD and ICA512bdc/IA-2 autoantibodies. Diabetes 1996;45:926-33.
14. 14 Kallmann BA, Huther M, Tubes M et al. Systemic bias of cytokine production toward cell-mediated immune regulation in IDDM and toward humoral immunity in Graves disease. Diabetes 1997; 46:237-43.
15. 15 Armant M, Rubio M, Delespesse G, Safati M. Soluble CD23 directly activates monocytes to contribute to the antigen-independent stimulation of resting T cells. J Immunol 1995;155:4868-75.
16. 16 Gladstone P, Nepom GT. The prevention of IDDM. Injecting insulin into the cytokine network. Diabetes 1995;44:858 -61.
17. 17 Ploix C, Bergerot I, Fabien N, Perche S, Moulin V, Thivolet C. Protection against autoimmune diabetes is associated with the presence of IL-4 type T-cells in the pancreas and pancreatic lymph nodes. Diabetes 1998;47:39-44.
18. 18 Stadler WM, Rybak ME, Vogelzang NJ. A phase II study of subcutaneous recombinant human interleukin-4 in metastatic renal cell carcinoma. Cancer 1995;76:1629-33.